Pitcairn’s Sage Therapeutics SAGE Stock Holding History

Pitcairn’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,011	Closed	-$227K	–	639
2021 Q2	$227K	Buy	4,011 +585	+17%	+$41.4K	0.02%	567
2021 Q1	$257K	Buy	+3,426	New	+$281K	0.02%	527

Other funds holding SAGE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Pitcairn's SAGE Position: Q3 2021 in Review

Pitcairn sold out of Sage Therapeutics (SAGE) in Q3 2021, closing a stake of 4,011 shares — an estimated $227K sold.

Pitcairn first reported a position in SAGE in Q1 2021 and held it in 2 quarters. The position peaked at $257K in Q1 2021. 225 funds tracked by Wall St. Rank hold SAGE as of Q3 2021.

Pitcairn reported no remaining Sage Therapeutics position as of Q3 2021 after selling out during the quarter.
Pitcairn sold 4,011 Sage Therapeutics shares in Q3 2021, an estimated $227K.
Pitcairn first reported a position in Sage Therapeutics in Q1 2021 and held it in 2 quarters.
Pitcairn's Sage Therapeutics position peaked at $257K in Q1 2021.
225 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2021.

Based on Pitcairn's 13F filing for Q3 2021, filed 10 Nov 2021.